The Committee for Medicinal Products for Human Use (CHMP) issued positive opinions regarding the drug’s application for adults and adolescents. Rinvoq, already cleared for several other autoimmune conditions, is currently a primary revenue driver for the North Chicago-based firm. AbbVie projects that total sales for the drug will exceed $10 billion throughout the current year.
In section Market Quotes
AbbVie Secures European Recommendation for Rinvoq Expansion
A key European regulatory committee has recommended expanding the approval of AbbVie’s blockbuster drug Rinvoq to treat severe alopecia areata and non-segmental vitiligo. If the European Commission follows this advice, the medication would become the first systemic treatment option available across Europe for patients battling the most common form of vitiligo.
While the European Commission typically aligns with CHMP recommendations, a final regulatory decision is expected in the coming months. For patients, the approval would mark a significant shift in managing non-segmental vitiligo, which often manifests as persistent, symmetrical white skin patches, and severe alopecia areata, characterized by varied patterns of hair loss.
Comments (0)
No comments yet. Be the first!